Rice Hall James & Associates LLC Sells 533 Shares of Haemonetics Co. (NYSE:HAE)

Rice Hall James & Associates LLC cut its holdings in shares of Haemonetics Co. (NYSE:HAE) by 1.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,331 shares of the medical instruments supplier’s stock after selling 533 shares during the period. Rice Hall James & Associates LLC owned approximately 0.09% of Haemonetics worth $3,916,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Capital Research Global Investors lifted its holdings in shares of Haemonetics by 2.3% during the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares in the last quarter. Vanguard Group Inc. lifted its stake in Haemonetics by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after buying an additional 25,451 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Haemonetics by 3.2% in the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after buying an additional 101,029 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Haemonetics by 7.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock worth $70,697,000 after acquiring an additional 59,670 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Haemonetics by 27.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock worth $60,888,000 after acquiring an additional 152,098 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Anila Lingamneni sold 2,136 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares in the company, valued at approximately $1,926,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Anila Lingamneni sold 2,136 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the transaction, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stewart W. Strong sold 4,312 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. Insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HAE. BTIG Research initiated coverage on shares of Haemonetics in a research note on Tuesday. They issued a “buy” rating and a $112.00 target price for the company. Barrington Research increased their price objective on Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Citigroup dropped their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Finally, Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research note on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.40.

Haemonetics Stock Up 1.7 %

HAE stock opened at $73.94 on Wednesday. The company has a market cap of $3.78 billion, a price-to-earnings ratio of 32.29, a P/E/G ratio of 1.33 and a beta of 0.30. Haemonetics Co. has a twelve month low of $70.74 and a twelve month high of $97.97. The business has a 50 day moving average price of $82.01 and a two-hundred day moving average price of $84.03. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. Haemonetics’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 earnings per share. Analysts anticipate that Haemonetics Co. will post 4.58 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.